GlassScriptPhysician profile
Monika Mannan
NPI 1831806520
$3,642.88
in general payments reported to CMS, 2019-2025
20 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $43.62 · 2023: $916 · 2024: $1,154 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,223 · Education: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,223.43 |
| Education | $375.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $606.79 | 2022-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $435.80 | 2023-2025 | Dupixent |
| Genzyme Corporation | $382.52 | 2023-2025 | |
| Abbvie INC. | $376.81 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $301.92 | 2023-2024 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $286.08 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $168.22 | 2023 | Sotyktu |
| Galderma Laboratories, L.P. | $156.68 | 2025 | Nemluvio |
| Ucb, INC. | $147.17 | 2025 | Bimzelx |
| Amgen INC. | $132.50 | 2023-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $100.95 | 2024-2025 | |
| Janssen Biotech, INC. | $97.73 | 2024-2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $90.76 | 2025 | Cabtreo |
| Pfizer INC. | $55.71 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $52.68 | 2025 | Sofdra |
| Leo Pharma INC. | $48.14 | 2025 | Anzupgo |
| Arcutis Biotherapeutics, INC. | $44.39 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $39.74 | 2024 | Vtama |
| Organon LLC | $23.30 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monika Mannan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.